Vestal Point Capital LP Purchases 12,677 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Vestal Point Capital LP grew its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 11.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 124,677 shares of the biotechnology company’s stock after purchasing an additional 12,677 shares during the quarter. Vestal Point Capital LP owned approximately 2.54% of Atara Biotherapeutics worth $1,014,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ATRA. Price T Rowe Associates Inc. MD increased its stake in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after purchasing an additional 4,903,159 shares in the last quarter. FMR LLC increased its holdings in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics during the 2nd quarter worth approximately $79,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Atara Biotherapeutics during the second quarter valued at approximately $53,000. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Stock Performance

Atara Biotherapeutics stock opened at $12.18 on Friday. Atara Biotherapeutics, Inc. has a twelve month low of $6.50 and a twelve month high of $39.50. The company’s 50-day moving average price is $9.54 and its 200-day moving average price is $10.03.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the prior year, the business earned ($16.50) EPS. As a group, equities analysts forecast that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a research note on Friday, August 16th. Canaccord Genuity Group lifted their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Hold” and a consensus target price of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.